Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):456–462. doi: 10.1097/QAI.0000000000002052

Table 2.

Serious adverse outcomes occuring in participants with enrollment HIV-RNA <3000 c/mL

N N patients with event Total events Rate Hazard ratio (95% CI) p
Grade 4 adverse events Def 579 17 17 0.97 1.0
Imm 555 16 18 0.95 0.97 (0.49, 1.92) 00.935
Death* Def 579 3 3 0.17 1.0
Imm 555 5 5 0.29 1.74 (0.41, 7.25) 0.576
Any hospitalisation Def 579 56 65 3.34 1.0
Imm 555 58 82 3.65 1.09 (0.75, 1.57) 0.648
Any of above combined Def 579 61 72 3.67 1.0
Imm 555 64 90 4.04 1.10, (0.77, 1.56) 0.595

Rate = rate of first events per 100 person years

Hazard ratio is for time to first event